166 results about "Brain natriuretic peptide" patented technology

The present invention provides reagents and assays for the quantification of hBNP in biological fluid samples such as plasma or serum. Antibodies are provided which are monospecific to epitopes comprising the amino acid sequences 5-13, 1-10 and 15-25 of hBNP. These antibodies, and peptide fragments containing these sequences, can be employed in the assays of the invention, which may be carried out in a sandwich format or a competition format.

The invention concerns methods for treating cardiac remodeling in a subject who has undergone myocardial injury, said method comprising the administration of natriuretic peptide to said subject. Preferably the natriuretic peptide is brain natriuretic peptide. The invention also concerns methods for treating structural heart disorders arising from myocardial injury, said method comprising the administration of a natriuretic peptide to a patient in need thereof.

The present invention describes compositions and methods designed to determine the presence or amount of biologically active natriuretic peptides, or their fragments, in a sample. The degradation of natriuretic peptides is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the quantity of proteolytic enzymes present; etc. This degradation can produce circulating amounts of natriuretic peptides having reduced or lost biological function. The present invention provides, inter alia, assays designed to accurately measure biologically active natriuretic peptides, and compositions to inhibit a previously unknown pathway for degradation of natriuretic peptides.

Natriuretic peptide fusion proteins comprising natriuretic peptides linked to antibody Fc domains, nucleic acid molecules encoding the fusion proteins disclosed herein, expression vectors expressing said fusion proteins, pharmaceutical compositions comprising said fusion proteins, and methods for their therapeutic use are disclosed.

The invention relates to a kit for detecting brain natriuretic peptide in blood serum and provides the kit for detecting brain natriuretic peptide by nano microsphere immunonephelometry, which has the characteristics of no need of dilution of a sample, simple operation, high precision, good repeatability and suitability for a clinically common used automatic biochemical analyzer, in order to solve technical problems. The invention adopts a technical scheme that the kit for detecting the brain natriuretic peptide by nano microsphere immunonephelometry comprises the following components: a, a reagent R1 which comprises buffer solution, a preservative, a stabilizing agent, an electrolyte, a surfactant, and the balance of water; b, a reagent R2 which comprises buffer solution, nano microspheres combined with brain natriuretic peptide antibodies and a preservative, wherein the diameter of the microspheres is 50 to 150 nm; and c, a reference calibration material which comprises buffer solution, a stabilizing agent, a preservative, a recombinant brain natriuretic peptide pure product which is added in a corresponding amount according to the required concentration of the BNP (brain natriuretic peptide) reference calibration material, and the balance of water.

The invention provides isolated and purified nucleic acid molecules encoding a natriuretic peptide useful in methods to inhibit or prevent heart failure.

Immunoassays and antibodies useful in conducting them for human and canine brain natriuretic peptide are described.

The invention provides the construction for a farnesyl pyrophosphoric acid synthetase RNA (Ribonucleic Acid) interference recombinant lentivirus vector, which comprises the following steps of: sieving the most effective target sequence of an FDS (farnesyl diphosphate synthase) gene RNAi (RNA interference) in a tool cell 293T cell, synthesizing the double-stranded DNA of the most effective target sequence, connecting to a pGCSIL-GFP vector and successfully constructing the recombinant vector through enzyme cutting, sequencing and identification. Researches indicate that the constructed RNA interference vector LV-sh-FDS can downwards modulate the expression of an FDS mRNA (Messenger RNA) level in a neonatal rat cardiac myocyte, simultaneously can downwards modulate the expression of myocardial hypertrophy markers such as cell areas and marker genes beta-MHC (Myosin Heavy Chain) and BNP (Brain Natriuretic Peptide), additionally can effectively inhabit the activity of RhoA while downwards modulating the FDS, can be applied in preparing medicaments for treating myocardial hypertrophy diseases and also can be applied in preparing medicaments for cholesterol metabolic control.

A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and / or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).

Novel BNP variants. The novel BNP variants according to the present invention may optionally be used for diagnosis of a BNP variant-detectable disease as described herein.

The invention disclosed herein relates to oxidized forms of brain natriuretic peptide (BNP), particularly human BNP (hBNP). The disclosed invention relates to oxidized forms of B-type natriuretic peptide (BNP), which is useful as a marker for cardiovascular disease

The invention provides a method for soluble expression of recombinant protein of a human brain natriuretic peptide (Human Brain Natriuretic Peptide, hBNP). The method comprises the following steps: 1) obtaining a recombinant gene, namely obtaining the recombinant gene His-DsbAmut-BNP of expressing the recombinant protein of the human brain natriuretic peptide, wherein the sequence of the recombinant gene comprises a purified tag gene sequence, a molecular chaperone protein gene sequence, a protease recognition site sequence and a human brain natriuretic peptide sequence, which are sequentially arranged along the direction from 5' to 3'; 2) obtaining recombinant plasmids, namely inserting the recombinant gene obtained in the previous step into a carrier vector, so as to obtain the recombinant plasmids containing the recombinant gene; 3) obtaining genetically engineered bacterium, transferring the recombinant plasmids obtained in the previous step into host cells to obtain the genetically engineered bacterium; 4) expressing exogenous genes, fermenting the genetically engineered bacterium, and expressing fusion protein containing the human brain natriuretic peptide; 5) purifying target protein, splitting thallus, collecting fusion protein, removing molecular chaperone and carrying out chromatographic purification by protease digestion, so as to obtain the recombinant protein of the human brain natriuretic peptide.

The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth in a mammalian host. In specific embodiments, the compounds are useful in the treatment of congestive heart failure.

The invention belongs to the field of medicine, particularly relates to a diagnostic technique of heart failure, and specifically relates to a B cell epitope peptide segment of amino-terminal pro-brain natriuretic peptide. An amino acid sequence is shown in SEQ ID NO:4 or SEQ ID NO:5. The prepared specific antibody can be used as a diagnostic reagent of heart failure. The amino-terminal pro-brain natriuretic peptide prepared by the invention is high-purity monomer recombinant protein of the amino-terminal pro-brain natriuretic peptide. The protein can be used for immunogen and screening collagen prepared from an antibody, and can be simultaneously used as a calibrator when the amino-terminal pro-brain natriuretic peptide is built to carry out quantitative detection. A monoclonal antibody prepared by immune mice at the B cell epitope peptide segment of the amino-terminal pro-brain natriuretic peptide has the advantages of high purity (SDS-PAGE detection purity greater than 96%), high valence (the valence of ELISA up to 1:512000), good specificity, mass preparation, and the like.

The invention discloses an optical biosensor for detecting brain natriuretic peptide (BNP) and a preparation method of a reagent thereof, relating to the biosensing technology. A sensor reaction zone is a capillary channel filled with magnetic nano probe solution, the inner surface of the channel is assembled with a layer of hydrophilic nano material, the upper surface of the channel is an euphotic insulating encapsulation layer with an injection hole, the side surface of the channel is encapsulated by plastics, the two ends thereof encapsulated with plastics are respectively provided with a controllable electromagnet. The preparation method of the reagent is as follows: preparing magnetic nano probes, fully reacting the magnetic nano probes, a brain natriuretic peptide (BNP) sample to bedetected and specificity BNP antigen marked by a marker under the united action of the electromagnet and the capillary channel, forming a compound of magnetic nano probes, BNP antigen to be detected and marked antibody, and adding substrate for catalytic luminescence or exciting luminescent quantum dots for luminescence. By the sensor detection system, the BNP concentration can be rapidly detected. The sensor in the invention can rapidly detect the BNP concentration in a sample, and has the characteristics of high specificity, high sensitivity, a great quantity of saved biological reagent andthe like.

The invention relates to a cardiac muscle control material, a preparation method therefor, a detection kit and a detection device for cardiac muscle. The cardiac muscle control material comprises quality control component and protection component, the quality control component comprises at least one of B-type natriuretic peptide, D-dimer, NT-proBNP, cardiac troponin I, myoglobin, creatine kinase isozyme and cardioid fatty acid binding protein and heart fatty acid binding protein. The protective component comprises 5 mM to 100 mM of a buffer agent, 0.5 % to 5% by weight of an excipient, 0.05 mMto 5 mM of an antioxidant, 0.05 mM to 15 mM of a protease inhibitor, 0.5% to 10% by weight of a stabilizer and 0.01% to 2% by weight of a surfactant. The cardiac muscle control material disclosed bythe invention is good in stability.

The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and / or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

The invention relates to a preparation method for a brain natriuretic peptide antigen photoelectrochemical sensor based on a CeO2-CdS weakened type. The invention uses CeO2-CdS as a substrate materialand irradiates with visible light to obtain a photocurrent. Energy bands of the CdS and the CeO2 match well, so that efficiency of photoelectric conversion is greatly improved. The SiO2 / PDA-Ag nanocomposite has large steric hindrance, and energy transfer exists between Ag nanoparticles and the substrate CdS, so that photoelectric response is double weakened, change value of the photoelectric response is increased, thus sensitivity of the sensor is improved. Detection of brain natriuretic peptide antigen is achieved according to different influences of objects to be tested with different concentrations on intensity of photoelectric signals. A detection limit is 0.05 pg / mL.

An isolated chimeric peptide consisting of one or two added peptides and an object peptide wherein the added peptide is bonded to the N-terminus, the C-terminus or both of the object peptide, wherein if the added peptides are bound to both terminals, the two added peptides may be the same or different; and physiological activity of the object peptide is still retained, wherein the object peptide is a natural physiologically active peptide selected from the group consisting of an atrial natriuretic peptide, a brain natriuretic peptide, a C-type natriuretic peptide, motilin, a glucagon-like peptide 1, parathyroid hormone, and calcitonin, or a derivative of any thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.

The invention provides a homogeneous fluorescence detection novel method of brain natriuretic peptide (BNP) with high sensitivity, high selectivity and low cost. The method comprises the following steps of through constructing a graphene oxide / fluorescent dye-labeled nucleic acid aptamer composite probe, using a fluorescence quenching effect of the graphene oxide to the dye to reduce a detected fluorescent background signal; when BNP is added and a nucleic acid aptamer make the fluorescent dye be far away from the graphene oxide through a specific molecular recognition effect, recovering a fluorescence signal of the dye, and establishing a linear working curve based on changes of BNP concentration and fluorescence intensity; and finally, through testing a fluorescence intensity change value after the sample is added and substituting into the working curve, calculating and acquiring accurate concentration of the BNP in a clinical sample. Various immunoassays have cross reaction due to usage of antibody recognition. By using the method of the invention, the above disadvantage is overcome; interferences of related peptides and the like are avoided; the method has advantages of simpleness, speediness, low cost, high sensitivity, high selectivity and the like; and the method can be used for quantitative detection of the BNP in blood of patients in clinical application, and can be used for timely diagnosis, treatment guidance and prognosis prompting.

The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies.

The invention relates to the technical field of fluorescence immunochromatography in medical immunology and in particular relates to a cardiac troponin I / N-terminal pro-brain natriuretic peptide / D-dimer three-in-one detection kit and a preparation method. The cardiac troponin I / N-terminal pro-brain natriuretic peptide / D-dimer three-in-one detection kit is provided with a test paper card and is characterized in that the test paper card is provided with a PVC (Polyvinyl Chloride) plate, a sample pad, a conjugate pad, a nitrocellulose membrane and a water absorption pad from top to bottom, wherein the conjugate pad is adsorbed with three monoclonal antibody-microsphere coupled compounds, and three monoclonal antibodies are labeled with rare-earth Eu<3+> fluorescent microspheres respectively and comprise anti-cardiac troponin I, anti-N-terminal pro-brain natriuretic peptide and anti-D-dimer; the diameter of the rare-earth fluorescent microspheres is 150nm and the rare-earth fluorescent microspheres contain a rare-earth lanthanide element Eu<3+>, are stable under a basic state and emit fluorescent light with the wavelength of 615nm under the action of an excitation light source with the wavelength of 337nm; the monoclonal antibodies are monoclonal antibodies obtained by purifying and mixing and are selected from 2 to 6 different monoclonal antibody cell strains which are epitope-tagged with different antigens including cardiac troponin I, N-terminal pro-brain natriuretic peptide and D-dimer respectively. The cardiac troponin I / N-terminal pro-brain natriuretic peptide / D-dimer three-in-one detection kit has the advantages of simplicity and convenience for operation, rapid reaction, high sensitivity, high specificity and the like.

The invention discloses a magnetic particle chemiluminiscence micro-fluidic chip for detecting the n-terminal portion of brain natriuretic peptide in whole blood. The micro-fluidic chip comprises a top plate (1) and a base plate (2), wherein an air pump (3), a sample adding port (4), a sample filling area (12), a labelled antibody storage pool (5) and a sample mixing area (13) on the top plate (1) are sequentially connected, a filtering area (6), a magnetic particle coating area (7), a cleaning area (14) and a detection area (8) on the base plate (2) are sequentially connected, and the detection area (8) on the base plate (2) is connected with a cleaning fluid storage pool (9) and a luminous substrate liquid storage pool (10) through a liquid releasing channel (16).

The invention relates to a nesiritide preparation method using gene engineering technology. The method includes: artificial synthesis of corresponding gene of human nesiritide BNP active position 32 amino acid, combining it with 3'end of mutated CMP-3-deoxy-D-manna-octulosonic acid synthase gene, in the recombinant gene the enterokinase identification cutting point is contained, cloning the recombinant gene into methanol nutrition type yeast Pichia expression vector, thus obtaining recombinant gene highly expressed engineered yeast, fermenting the engineered yeast ,extracting , proceeding chromatography and purifying to produce recombinant protein, cutting with enterokinase, separating and purifying, obtaining recombinant human nesiritide. The recombinant peptide has huaman nesiritide activity after in vitro experiment.

The present invention relates to a method for determining a risk whether an individual will suffer from a cardiovascular adverse event as a consequence of cardiac stress testing, comprising the steps of (a) measuring, preferably in vitro, the level of placenta growth factor, wherein (b) if the level of the placenta growth factor is at least increased, then the individual is at least at risk of suffering from an adverse event as a consequence of cardiac stress testing. In a further embodiment, additionally another marker is measured, particularly a natriuretic peptide, most particularly NT-proBNP. The present invention allows to stratify patients according to the environment and conditions under which cardiac stress testing should be carried out.

The invention discloses a fused protein from human brain natriuretic peptide(BNP)2 and human serum albumin (HSA) and the preparation method thereof, belonging to the technical field of long-effetive recombinant fused protein drugs. The invention introduces OE-PCR technology to splice two BNP cDNAs(called (BNP)2 for short) and HAS cDNA, without adding any connecting peptide therebetween, obtaining fused gene(BNP)2-HSA cDNA which is then integrated with the chromosome of the host and expresses in the expression system of the host. The fused protein of the invention comprises a first region with at least 85% of the sequence congenetic with human brain natriuretic peptide and a second region with at least 85%of the sequence congenetic with human serum albumin. Under the premise of not being changed in characteristics, the fused protein is capable of the substitution, deletion or addition of specific amino acid residues. The fused protein maintains the physiological characteristics and improves the solubility of human brain natriuretic peptide and prolongs the half life of human brain natriuretic peptide within human body; therefore the fused protein is of good application prospect in pharmacy.

A quick quantitative detecting device and method for simultaneously detecting human brain natriuretic peptides and N-terminal pro-brain natriuretic peptides are characterized in that the device is composed of human brain natriuretic peptide (BNP) test paper, N-terminal pro-brain natriuretic peptide (NT-ProBNP) test paper, a double link clamping shell and an immune chromatography result interpretation recorder, the BNP test paper and the NT-ProBNP test paper are mutually independent, and corresponding standard curves and judging methods are arranged in the immune chromatography result interpretation recorder. The immune chromatography result interpretation recorder is an optical detection system and is used for quantitative judging of detection results. The detection range for the BNP and the detection range for the NT-ProBNP are 0.1-10ng / mL and 0.2-20ng / mL respectively. The detection is finished in 15-20 minutes. The quick quantitative detecting device and method have the advantages of detecting in a combined mode, and being simple and convenient to operate, quick in response, accurate in result, suitable for on-site detection and the like, and suitable for requirements of clinic for more accurate, simpler and more convenient detection.

An in vitro method of determining activation or inactivation of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (B3NP) hormonal systems, the method comprising simultaneously detecting the presence or amount of atrial and brain natriuretic peptide prohormones (proANP and proBNP) or fragments thereof in a sample.